跳轉至內容
Merck
全部照片(2)

重要文件

R5280

Sigma-Aldrich

Anti-phospho-RanGAP1 (pSer428) antibody produced in rabbit

~1.0 mg/mL, affinity isolated antibody, buffered aqueous solution

同義詞:

Anti-Ran GTPase activating protein-1

登入查看組織和合約定價


About This Item

分類程式碼代碼:
12352203
NACRES:
NA.41

生物源

rabbit

共軛

unconjugated

抗體表格

affinity isolated antibody

抗體產品種類

primary antibodies

無性繁殖

polyclonal

形狀

buffered aqueous solution

分子量

antigen ~60 kDa

物種活性

human

濃度

~1.0 mg/mL

技術

indirect immunofluorescence: 5-10 μg/mL using HeLa cells
western blot: 1.5-3.0 μg/mL using HEK-293T cell lysate expressing human RanGAP1

UniProt登錄號

運輸包裝

dry ice

儲存溫度

−20°C

目標翻譯後修改

phosphorylation (pSer428)

基因資訊

human ... RANGAP1(5905)

一般說明

The gene for Ran GTPase activating protein 1 (RANGAP1) is located on the human chromosome 22q13.2.

特異性

Anti-phospho-RanGAP1 (pSer428) specifically recognizes human phospho-RanGAP1 (pSer428) (not yet tested in other species).

應用

Anti-phospho-RanGAP1 (pSer428) antibody produced in rabbit has been used in western blotting.

生化/生理作用

However, the SUMO-1 modification induces the interaction of RanGAP1 with the interphase nuclear pore complex (NPC) through binding to the nucleoporin Ras-related nuclear protein 1 binding protein 2 (RANBP2) and to Ubc9. RanGAP1 is phosphorylated on residues Thr409, Ser442 and Ser428. Phosphorylated RanGAP1 may aid the translocation of specific SUMO target proteins to RanBP2′s catalytic domain.
Ran GTPase Activating Protein 1 (RanGAP1) is a key regulator of Ran activity, by specifically inducing its GTPase activity. RanGAP1 is conjugated to the small ubiquitin-related modifier protein (SUMO-1). The activity of RanGAP1 is not substantially altered by SUMO-1 modification. Phosphorylation ensues before the breakdown of the nuclear envelope and is sustained during the entire mitosis process.

外觀

0.01M 磷酸缓冲盐溶液,pH 7.4,含 15mM 叠氮化钠。

儲存和穩定性

For continuous use, store at 2–8 °C for up to one month. For extended storage, freeze in working aliquots. Repeated freezing and thawing, or storage in “frost-free” freezers is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilutions should be discarded if not used within 12 hours.

免責聲明

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

未找到適合的產品?  

試用我們的產品選擇工具.

儲存類別代碼

10 - Combustible liquids

水污染物質分類(WGK)

nwg

閃點(°F)

Not applicable

閃點(°C)

Not applicable

個人防護裝備

Eyeshields, Gloves, multi-purpose combination respirator cartridge (US)


分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

ON 01910. Na inhibits growth of diffuse large B-cell lymphoma by cytoplasmic sequestration of sumoylated C-MYB/TRAF6 complex
Dai YH, et al.
Translational Research, 175(11), 129-143 (2016)
Insights into E3 ligase activity revealed by a SUMO-RanGAP1-Ubc9-Nup358 complex
Reverter D and Lima CD
Nature, 435(7042), 687-687 (2005)
Jomon Joseph et al.
Current biology : CB, 14(7), 611-617 (2004-04-06)
RanGAP1 is the activating protein for the Ran GTPase. Vertebrate RanGAP1 is conjugated to a small ubiquitin-like protein, SUMO-1. This modification promotes association of RanGAP1 with the interphase nuclear pore complex (NPC) through binding to the nucleoporin RanBP2, also known
Ran GTPase-activating protein 1 is a therapeutic target in diffuse large B-cell lymphoma
Chang K C, et al.
Testing, 8(11), e79863-e79863 (2013)
Kung-Chao Chang et al.
PloS one, 8(11), e79863-e79863 (2013-11-14)
Lymphoma-specific biomarkers contribute to therapeutic strategies and the study of tumorigenesis. Diffuse large B-cell lymphoma (DLBCL) is the most common type of malignant lymphoma. However, only 50% of patients experience long-term survival after current treatment; therefore, developing novel therapeutic strategies

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務